Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7295 · 1 trial · 1 indication
PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2)
| Arm | Type | Description |
|---|---|---|
| AZD7295 | EXPERIMENTAL | - |
| Matched placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD7295 | DRUG | Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days. |
| Placebo comparator | DRUG | Placebo capsules |
Inclusion Criteria: * Healthy male or female volunteers, aged 18-65 years. Exclusion Criteria: * Previous exposure to AZD7295, clinically relevant disease.
AZD7295 is an investigational small molecule being developed by cbdMD, Inc. (ticker: YCBCD). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its pharmacokinetics, which is how the body absorbs, distributes, metabolizes, and excretes the drug.
AZD7295 is being studied for use in healthy volunteers. The completed Phase 1 trial focused on the pharmacokinetics of AZD7295 capsules, meaning it assessed how the drug behaves in the body. It is not yet approved for any medical condition and remains in clinical development.
AZD7295 is being developed by cbdMD, Inc., a company traded under the ticker symbol YCBCD. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetic profile in healthy subjects.
AZD7295 is in Phase 1 clinical development. The drug has completed one Phase 1 trial, which was a pharmacokinetic study in healthy volunteers. It is still investigational and has not been approved by regulatory authorities.
AZD7295 has one completed clinical trial, identified as NCT01097408, titled "Pharmacokinetics of AZD7295 Capsules." This Phase 1 study enrolled 12 healthy participants in the United Kingdom and was a randomized, double-blind, placebo-controlled trial. The trial has been completed.